Home / Executive Moves / Erin Andre Named SRI Chief People Officer, Greg Kovacs to Serve as Biosciences Division President

Erin Andre Named SRI Chief People Officer, Greg Kovacs to Serve as Biosciences Division President

SRI International logoSRI International has appointed Greg Kovacs, a 25-year professor at Stanford University, as president of its biosciences division and named Erin Andre, former chief human resource officer of Convergys, as the nonprofit’s chief people officer.

Kovacs will collaborate with other executives of SRI and the biosciences division to  implement research, development and commercialization strategies, SRI said Thursday.

“Greg will contribute vision, scientific depth and entrepreneurial spirit to further strengthen the capabilities and impact of the Biosciences Division, ” noted SRI CEO William Jeffrey.

Kovacs has taught electrical engineering and medicine at Stanford University, where he also helped spearhead the establishment of the university’s bioengineering department.

He also co-founded molecular diagnostics company Cepheid as well as previously served as director at the Defense Advanced Research Projects Agency‘s microelectronics technology office and as an investigation scientist at NASA.

Andre will oversee SRI’s human resources operations such as recruitment, talent development, collaborative and inclusive culture, rewards, wellness and benefits programs, SRI added.

He previously held HR leadership roles at ABM Industries,  National Energy & Gas Transmission and PG&E.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.